$RBSH 350k Mrkt Cap, 9mil Float, Completed Turnaround Last Month$RBSH This has a 9mil Float, MM's walked it down on low Vol after a recent RS... Volume has come back with over 10x the 10Day Ave Vol, Accumulation out the roof, all indicators pointing to breakout soon...
The Co just Completed a turnaround, New Officers Juts took over along with Ticker & Name Change...( Formerly Inspyr Therapeutics, now Rebus Holdings Inc )
They have Clinical Updates Coming, multiple patents, and also just reacquired some additional patents. See Link Below
15 U.S Patents, 40 Pending World Wide Applications - Clinical Trials Happening Currently -
Google - inspyr-therapeutics-announces-holding-company-110000130 (Sorry, Can not post Link)
So understand this - For this to have a $40 Million Market Cap which it did in 2021 - Now with the current SS, the price of $RBSH needs to be at $4 - Currently at $0.04 Cents = 1000% Up from here. No pumping needed, look into Inspyr.
- FDA Meeting Held 2021
- Clinical Updates Coming
- Inspyr had a market cap of 100 Million
- Current market cap =350,000
- OS is 10 Million
- Float - 9 Million
Took positions .035-.04 so far, will add on .05 Break
inspyrtherapeutics dot com
rebus-corp dot com
Patents + FDA Clinical Trials -
Developing targeted cancer therapeutics that delivers a potent, unique & patented drug that directly treats breast, prostate, bladder, kidney, and lung cancer.
Inspyr Therapeutics, Inc. is an integrated clinical-stage biopharmaceutical company focused on the development of targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder, kidney, and lung cancer based on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark, Inspyr has a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. The pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist.
Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company’s drug candidates within a tumor. Inspyr’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.
The company involves in the discovery and development of pro-drug cancer therapeutics. A pro-drug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. Its pro-drug development candidates include G-202, which is in Phase I clinical trials and targets the blood vessels of various solid tumors; and G-114, G-115, and Ac-GKAFRR-L12ADT, which are in pre-clinical animal models for the treatment of prostate cancer.
